Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Lung Cancer Health Center

Font Size

Tarceva May Improve Survival From Lung Cancer

Study Shows Drug Has Benefits as Initial Treatment of Some Advanced Lung Cancers
WebMD Health News
Reviewed by Laura J. Martin, MD

Oct. 11, 2010 - Patients whose advanced lung cancers bear the EGFR mutation survive two to three times longer if given initial treatment with Tarceva, a Chinese study suggests.

A Japanese study reported earlier this year suggests that a similar drug, Iressa, may also be most effective if given prior to standard chemotherapy.

Currently, patients with advanced lung cancer have a dim prognosis. Those who are relatively healthy are given a double chemotherapy that extends survival, but only for a few months. Caicun Zhou, MD, PhD, of Shanghai Pulmonary Hospital at Tongji University in China, compared first-line treatment with Tarceva to a powerful double chemotherapy regimen in 165 patients with advanced lung cancer.

Median progression-free survival -- that is, time until the cancer got worse -- was only 4.6 months for standard chemotherapy but was 13.1 months for patients taking Tarceva.

Moreover, patients taking Tarceva suffered far fewer side effects of therapy than those on standard chemo.

Zhou reported the study findings at this week's meeting of the European Society for Medical Oncology in Milan, Italy.

Not all lung cancers carry the EGFR mutation. But those that do are sensitive to two drugs that target the EGFR enzyme: Genentech's Tarceva, and AstraZeneca's Iressa.

Early clinical trials tested the drugs as second-line therapy. But the Zhou study, and an earlier Japanese study by Makoto Maemondo, MD, PhD, and colleagues, suggest that patients with EGFR lung cancers do best if given the drug initially.

A raft of clinical trials are under way exploring how to capitalize on these findings. Most of them are using Tarceva or Iressa in combination with different agents.

This study was presented at a medical conference. The findings should be considered preliminary as they have not yet undergone the "peer review" process, in which outside experts scrutinize the data prior to publication in a medical journal.

Today on WebMD

Broken cigarette
Do you know the myths from the facts?
man with a doctor
Our health check will steer you in the right direction.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Lung cancer xray
See it in pictures, plus read the facts.
15 Cancer Symptoms Men Ignore
Lung Cancer Risks Myths and Facts
cancer fighting foods
Improving Lung Cancer Survival Targeted Therapy
Lung Cancer Surprising Differences Between Sexes
Pets Improve Your Health
Vitamin D
Lung Cancer Surgery Options